CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses. Get Wall ...

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

German vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost its manufacturing capacity for its potential COVID-19 vaccine. The loan – equivalent ...

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical ...

CureVac (NASDAQ:CVAC – Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer, BioNTech win bid to invalidate CureVac's UK COVID ...

CureVac Price Performance Shares of NASDAQ:CVAC opened at $2.87 on Monday. The stock has a market cap of $642.54 million, a price-to-earnings ratio of 5.22, a PEG ratio of 0.24 and a beta of 2.59 ...

Shares of CureVac are trading higher by 13.5% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.